<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628688</url>
  </required_header>
  <id_info>
    <org_study_id>KCT 011 (VOLGA)</org_study_id>
    <nct_id>NCT05628688</nct_id>
  </id_info>
  <brief_title>A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Insight® Pro Device for Evaluating Lymphatic and Venous Disorders (VOLGA)</brief_title>
  <acronym>VOLGA</acronym>
  <official_title>A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Insight® Pro Device for Evaluating Lymphatic and Venous Disorders (VOLGA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Koya Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Koya Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that the Insight Pro Device is safe and effective for use in detecting&#xD;
      lymphatic and venous disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      6. Clinical Hypotheses&#xD;
&#xD;
        1. The Insight Pro device can detect a difference in extracellular fluid volume through&#xD;
           bioimpedance and dielectric constant measurement.&#xD;
&#xD;
        2. The Insight Pro device can detect a difference in skin hardness or fibrositis through a&#xD;
           durometer measurement.&#xD;
&#xD;
        3. The Insight Pro device is safe for use as assessed by adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Edema Volume</measure>
    <time_frame>Acute - At day 0</time_frame>
    <description>Edema Volume detection by difference in extracellular fluid volume through bioimpedance and dielectric constant measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrosis</measure>
    <time_frame>Acute - At day 0</time_frame>
    <description>Durometer detection or Skin hardness (fibrosis) difference through a durometer measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety/AEs</measure>
    <time_frame>Acute - At day 0</time_frame>
    <description>Safety during use (via adverse event reporting)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LymVAS</measure>
    <time_frame>Acute - At day 0</time_frame>
    <description>Correlation with quality-of-life objective parameters using a lymphedema visual analog scale</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lymphedema</condition>
  <condition>Chronic Venous Insufficiency</condition>
  <condition>Edema</condition>
  <condition>Venous Insufficiency of Leg</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <description>Up to 50 subjects will be enrolled with unilateral or bilateral edema in the upper or lower extremity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Up to 50 patients will be enrolled from a healthy volunteer group as a control, with no edema.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Insight Pro Device for Diagnosis</intervention_name>
    <description>Insight Pro Device for Diagnosis of Lymphatic and Venous Disorders</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        (Test Group) - Up to 50 subjects will be enrolled with unilateral or bilateral edema in the&#xD;
        upper or lower extremity.&#xD;
&#xD;
        (Control Group) Up to 50 patients will be enrolled from a healthy volunteer group as a&#xD;
        control, with no edema.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Test group -&#xD;
&#xD;
          -  Males and females ≥ 18 years of age&#xD;
&#xD;
          -  Willing to sign the informed consent and deemed capable of following the study&#xD;
             protocol&#xD;
&#xD;
          -  Subjects must have primary or secondary unilateral or bilateral upper or lower&#xD;
             extremity edema&#xD;
&#xD;
          -  At the time of initial evaluation, individuals must be at least 3 months post-surgery,&#xD;
             chemotherapy and/or radiation treatment for cancer if applicable&#xD;
&#xD;
        Control group -&#xD;
&#xD;
          -  Males and females ≥ 18 years of age&#xD;
&#xD;
          -  Willing to sign the informed consent and deemed capable of following the study&#xD;
             protocol&#xD;
&#xD;
          -  Subjects must not have primary or secondary edema and self-describe general healthy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ● Inability or unwillingness to participate in all aspects of the study protocol&#xD;
             and/or failure to provide informed consent&#xD;
&#xD;
               -  Patients with exam results that would prevent safe and effective use of the study&#xD;
                  device (cellulitis, open-wounds, healing-wounds, etc.)&#xD;
&#xD;
               -  Diagnosis of active or recurrent cancer (&lt; 3 months since completion of&#xD;
                  chemotherapy, radiation therapy, or primary surgery for the cancer)&#xD;
&#xD;
               -  Patients with cardiac arrhythmia with pacemakers or other implanted electronic&#xD;
                  equipment&#xD;
&#xD;
               -  Patients must not have implanted metal hardware in the limbs&#xD;
&#xD;
               -  Patients undergoing external defibrillation&#xD;
&#xD;
               -  Diagnosis of Acute infection (in the last four weeks)&#xD;
&#xD;
               -  Diagnosis of acute thrombophlebitis (in last 2 months)&#xD;
&#xD;
               -  Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 2&#xD;
                  months&#xD;
&#xD;
               -  Diagnosis of congestive heart failure (uncontrolled)&#xD;
&#xD;
               -  Diagnosis of chronic kidney disease with acute renal failure&#xD;
&#xD;
               -  Women who are pregnant, planning a pregnancy or nursing at study entry&#xD;
&#xD;
               -  Participation in any clinical trial of an investigational substance or device&#xD;
                  during the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>November 28, 2022</last_update_submitted>
  <last_update_submitted_qc>November 28, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

